Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 26 min ago
PreprintCC BYChemRxiv

Pt(II)-Flavin Complexes As Anticancer And Antibacterial Agents

  • Maria Jesus Moran Plata1,2
  • Igor V. Esarev3,4
  • Nitin Kumar1,2
  • Laura Marretta5
  • Leo Pontfort6
  • Ana Cristina Carrasco1,2
  • Beatrice Bernadette Mascitti1,2
  • Alessio Terenzi5
  • Luisa Ronga6
  • Ingo Ott3,4
  • Luca Salassa1,2,7,8
8 affiliations
  1. 1Euskal Herriko Unibertsitatea UPV/EHU, Paseo Manuel de Lardizabal 3, Donostia, Spain, 20018
  2. 2Donostia International Physics Center, Paseo Manuel de Lardizabal 4, Donostia, Spain, 20018
  3. 3Institute of Medicinal and Pharmaceutical Chemistry
  4. 4Technische Universität Braunschweig
  5. 5Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche, Università degli Studi di Palermo, Viale delle Scienze, Edificio 17, Palermo, Italy, 90128
  6. 6CNRS, IPREM UMR, 2 Av. du Président Pierre Angot, Pau cedex, France, 64053
  7. 7Ikerbasque
  8. 8Basque Foundation for Science
Open at sourcePDFDOICite

Abstract

We report a new chelating pyridyl–imine ligand bearing a riboflavin-derived pendant group and its Pt(II) complexes 1 and 2, designed as cisplatin- and oxaliplatin-like derivatives. Both complexes reacted with DNA and a histone-derived peptide, with 1 showing markedly higher covalent reactivity. However, this trend was not reflected in biological activity. Complex 2 displayed micromolar antiproliferative effects and pronounced antibacterial activity, particularly against Bacillus subtilis, whereas 1 was inactive in the tested models. Cellular accumulation studies excluded enhanced Pt uptake as the origin of this difference. Fluorescence microscopy performed on Escherichia Coli and Bacillus subtilis indicated that 2 affects bacterial DNA and membrane potential, consistent with a dual antibacterial mechanism. Comparison with oxaliplatin and the free flavin ligands showed that both the Pt–oxalate fragment and the riboflavin-containing ligand are required for activity.

Related

  1. Development of P^N-Pd(II) Type Complexes Derived from Aliphatic Amines as Potential Antibacterial and Antifungal Agents.
    Michelle Acosta-Encinas, Andrés Amaya-Flórez, Jordi R Galindo +8
    Antibiotics (Basel, Switzerland)Peer-reviewedCC BYFull textOncologyEurope PMC
  2. Flavone-Based Anticancer Agents: Advances in Structure–Activity Relationships and Multitarget Mechanisms for Drug Design (2015–Present)
    Mmakwena M. Mmonwa, Malose J. Mphahlele
    MoleculesPeer-reviewedCC BY 4.0Pharmacology & toxicologyCrossref
  3. Lighting up cancer: latest discoveries in ruthenium(ii) polypyridyl complexes for anticancer photodynamic therapy.
    Pei Yi Tan, Ke Hui Lee, Kuan Teng Tan +6
    RSC advancesPeer-reviewedCC BY-NCFull textOncologyEurope PMC
  4. Novel Palladium(II) β-Diketonate Complexes: Synthesis, Dual Antimicrobial/Anticancer Activity, and Molecular Insights into DNA/Protein Interactions
    Marija Trifunović Stevanović, Nenad Joksimović, Jelena Petronijević +5
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0OncologyCrossref
  5. Risk Factors and Pathophysiological Mechanisms in Drug-Induced Interstitial Lung Disease Associated With Novel Anticancer Agents: A Scoping Review (2016-2026)
    Seiichiro Kuroda, Hidetoshi Ishii, Masaaki Ishibashi +1
    CureusPeer-reviewedCC BYFull textOncologyPharmacology & toxicologyEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@misc{plata2026ptiiflavin,
  title = {{Pt(II)-Flavin Complexes As Anticancer And Antibacterial Agents}},
  author = {Maria Jesus Moran Plata and Igor V. Esarev and Nitin Kumar and Laura Marretta and Leo Pontfort and Ana Cristina Carrasco and Beatrice Bernadette Mascitti and Alessio Terenzi and Luisa Ronga and Ingo Ott and Luca Salassa},
  howpublished = {ChemRxiv},
  year = {2026},
  month = sep,
  doi = {10.26434/chemrxiv.15009344/v1},
  url = {https://chemrxiv.org/doi/full/10.26434/chemrxiv.15009344/v1},
  note = {CC BY},
}
RIS
TY  - UNPB
TI  - Pt(II)-Flavin Complexes As Anticancer And Antibacterial Agents
AU  - Maria Jesus Moran Plata
AU  - Igor V. Esarev
AU  - Nitin Kumar
AU  - Laura Marretta
AU  - Leo Pontfort
AU  - Ana Cristina Carrasco
AU  - Beatrice Bernadette Mascitti
AU  - Alessio Terenzi
AU  - Luisa Ronga
AU  - Ingo Ott
AU  - Luca Salassa
PY  - 2026
DA  - 2026/09/23
PB  - ChemRxiv
DO  - 10.26434/chemrxiv.15009344/v1
UR  - https://chemrxiv.org/doi/full/10.26434/chemrxiv.15009344/v1
AB  - We report a new chelating pyridyl–imine ligand bearing a riboflavin-derived pendant group and its Pt(II) complexes 1 and 2, designed as cisplatin- and oxaliplatin-like derivatives. Both complexes reacted with DNA and a histone-derived peptide, with 1 showing markedly higher covalent reactivity. However, this trend was not reflected in biological activity. Complex 2 displayed micromolar antiproliferative effects and pronounced antibacterial activity, particularly against Bacillus subtilis, whereas 1 was inactive in the tested models. Cellular accumulation studies excluded enhanced Pt uptake as the origin of this difference. Fluorescence microscopy performed on Escherichia Coli and Bacillus subtilis indicated that 2 affects bacterial DNA and membrane potential, consistent with a dual antibacterial mechanism. Comparison with oxaliplatin and the free flavin ligands showed that both the Pt–oxalate fragment and the riboflavin-containing ligand are required for activity.
ER  -